Nabilone for non-chemotherapy associated nausea and vomiting and weight loss due to medical conditions a review of clinical effectiveness and guidelines
Nabilone is a synthetic drug belonging to the cannabinoid family. Cannabinoids are characterized by the active component delta-tetrahydrocannabinol. Despite the growing literature on the therapeutic benefits of synthetic cannabinoids, in Canada, nabilone remains approved exclusively for its use in t...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
July 27, 2017, 2017
|
| Edition: | Version: 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Nabilone is a synthetic drug belonging to the cannabinoid family. Cannabinoids are characterized by the active component delta-tetrahydrocannabinol. Despite the growing literature on the therapeutic benefits of synthetic cannabinoids, in Canada, nabilone remains approved exclusively for its use in the treatment of severe nausea and vomiting associated with cancer chemotherapy. The purpose of this report is to evaluate the clinical effectiveness and guidelines for the use of nabilone for nausea and vomiting or weight-loss due to medical conditions not associated with chemotherapy. This report serves as an update to CADTH's 2014 Rapid Response report. This previous report reviewed four low quality studies and was unable to make any strong conclusions pertaining to the effectiveness of nabilone for non-chemotherapy nabilone for nausea or weight loss |
|---|---|
| Item Description: | Preceded by: Nabilone for non-chemotherapy associated nausea and weight loss due to medical conditions : a review of the clinical effectiveness and guidelines / prepared by Canadian Agency for Drugs and Technologies in Health. [Ottawa] : Canadian Agency for Drugs and Technologies in Health, 12 September 2014 |
| Physical Description: | 1 PDF file (13 pages) |